Community Urology Service, Sussex Medical Centre, Brighton, UK.
St George's University of London Medical School, London, UK.
Minim Invasive Ther Allied Technol. 2022 Mar;31(3):456-461. doi: 10.1080/13645706.2020.1816554. Epub 2020 Sep 11.
The minimally invasive UroLift System procedure in moderate-to-severe benign prostate hyperplasia (BPH) refractory to medical treatment may be superior over other prostate procedures regarding its preserved sexual function post-operatively. We aimed to optimise patient selection criteria for the UroLift System.
Fifty-one men that underwent UroLift System surgery were retrospectively reviewed over >24 months. We evaluated the efficacy and safety of UroLift System, pre-operatively and at three, six, 12, and 24 months post-operatively, assessing the International Prostate Symptom Score (IPPS), urinary flow rates (Qmax), post void residual (PVR) bladder scan volumes and the International Index of Erectile Function (IIEF). Adverse events were assessed by Clavien-Dindo Classification.
The 51 men undergoing UroLift System had a success rate of 92.2% over 2 years, with improvements in Qmax, IPSS and PVR. IIEF was preserved in all cases. Adverse events were Clavien-Dindo grade 1, most commonly mild-to-severe dysuria (19.6%), and resolved spontaneously. Four patients failed to improve.
Patient-related selection criteria to optimise the UroLift System clinical outcomes include age, Qmax, PVR urine, median lobe, PSA levels, prostate volume, IPSS and IIEF scores. The UroLift System is safe and effective in moderate-to-severe BPH refractory to pharmacological treatments and avoids retrograde ejaculation.
对于药物治疗无效的中重度良性前列腺增生（BPH）患者，微创 UroLift 系统手术可能优于其他前列腺手术，因为其术后性功能保留更好。我们旨在优化 UroLift 系统的患者选择标准。
对 51 例行 UroLift 系统手术的男性患者进行回顾性研究，随访时间超过 24 个月。我们评估了 UroLift 系统的疗效和安全性，包括术前以及术后 3、6、12 和 24 个月的国际前列腺症状评分（IPSS）、尿流率（Qmax）、残余尿量（PVR）膀胱扫描体积和国际勃起功能指数（IIEF）。通过 Clavien-Dindo 分类评估不良事件。
51 例行 UroLift 系统手术的男性患者 2 年内成功率为 92.2%，Qmax、IPSS 和 PVR 均有改善。所有病例的 IIEF 均得以保留。不良事件为 Clavien-Dindo 1 级，最常见的是轻度至重度尿痛（19.6%），且自行缓解。有 4 例患者未得到改善。
为优化 UroLift 系统的临床疗效，患者相关的选择标准包括年龄、Qmax、PVR 尿液、中叶、PSA 水平、前列腺体积、IPSS 和 IIEF 评分。UroLift 系统在药物治疗无效的中重度 BPH 中安全有效，可避免逆行射精。
